HLVX (HilleVax) Debt-to-Asset : 0.13 (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is HilleVax Debt-to-Asset?

HilleVax's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $3.57 Mil. HilleVax's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $20.94 Mil. HilleVax's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $192.69 Mil. HilleVax's debt to asset for the quarter that ended in Dec. 2024 was 0.13.

HilleVax Debt-to-Asset Historical Data

The historical data trend for HilleVax's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HilleVax Debt-to-Asset Chart

HilleVax Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

5.99

1.25

0.12

0.15

0.13

HilleVax Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial												0.15	0.16	0.18	0.11	0.13

Competitive Comparison of HilleVax's Debt-to-Asset

For the Biotechnology subindustry, HilleVax's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HilleVax's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HilleVax's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where HilleVax's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

HilleVax Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

HilleVax's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3.57	+	20.943)	/	192.69
	=	0.13

HilleVax's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3.57	+	20.943)	/	192.69
	=	0.13

HilleVax (NAS:HLVX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

HilleVax Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of HilleVax's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

HilleVax Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HilleVax Inc (NAS:HLVX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

321 Harrison Avenue, Boston, MA, USA, 02118

Website

https://www.hillevax.com

HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

Executives

Robert Hershberg	director, officer: President and CEO	3005 FIRST AVENUE, SEATTLE WA 98121
Shane Maltbie	officer: Chief Financial Officer	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Aditya Kohli	director, officer: Chief Operating Officer	C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Frazier Life Sciences X, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Astrid Borkowski	officer: Chief Medical Officer	C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109
Nanette Cocero	director	C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100, BOSTON MA 02109
Fhmls X, L.l.c.	10 percent owner	601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Gary Dubin	director	C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109
Jaime Sepulveda	director	C/O HILLEVAX INC., 75 STATE STREET 100 - #9995, BOSTON MA 02109
Takeda Vaccines, Inc.	10 percent owner	75 SIDNEY STREET, CAMBRIDGE MA 02139
Shelley Chu	director	ONE WINTHROP SQUARE, SUITE 400, BOSTON MA 02110
Susan Michele Silbermann	director	C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Fhmls X, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Julie L. Gerberding	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
David A Socks	officer: CFO & Chief Business Officer	C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130